Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

SGEN

Seagen (SGEN)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SGEN
DataOraFonteTitoloSimboloCompagnia
09/01/202412:12IH Market NewsWall Street Highlights: HPE and Juniper Networks in Negotiations, Elliott Invests $1 Billion in Match Group, and MoreNASDAQ:SGENSeagen Inc
26/12/202312:12Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:SGENSeagen Inc
19/12/202300:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SGENSeagen Inc
18/12/202323:25Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:SGENSeagen Inc
15/12/202323:00PR Newswire (US)PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder CancerNASDAQ:SGENSeagen Inc
14/12/202314:47Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:SGENSeagen Inc
14/12/202314:29Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:SGENSeagen Inc
14/12/202314:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SGENSeagen Inc
14/12/202314:00Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:SGENSeagen Inc
12/12/202313:43Dow Jones NewsPfizer to Close $43 Billion Seagen Acquisition This WeekNASDAQ:SGENSeagen Inc
11/12/202301:30Business WireADCETRIS® (brentuximab vedotin) Plus Novel Immunotherapy Combination Delivers 100% Progression Free Survival at 12 months in Phase 2 Trial of Patients with Early Stage Classical Hodgkin LymphomaNASDAQ:SGENSeagen Inc
06/12/202314:15Business WireTUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progression-Free Survival in Patients with Previously Treated HER2-Positive Metastatic Breast CancerNASDAQ:SGENSeagen Inc
01/12/202300:04Dow Jones NewsAstellas, Seagen: Cancer Treatment Padcev Supplemental Biologics License Application Gets FDA Priority ReviewNASDAQ:SGENSeagen Inc
30/11/202323:00Business WireFDA Grants Priority Review for Supplemental Biologics License Application (sBLA) of PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder CancerNASDAQ:SGENSeagen Inc
14/11/202303:37Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:SGENSeagen Inc
14/11/202300:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SGENSeagen Inc
03/11/202317:00Business WireSeagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:SGENSeagen Inc
02/11/202318:00Business WireNew Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug ConjugateNASDAQ:SGENSeagen Inc
01/11/202313:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SGENSeagen Inc
01/11/202313:00Business WireSeagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline ProgressNASDAQ:SGENSeagen Inc
22/10/202316:30Business WireTIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 TrialNASDAQ:SGENSeagen Inc
22/10/202316:30Business WireGroundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder CancerNASDAQ:SGENSeagen Inc
20/10/202313:22IH Market NewsFriday’s Wall Street Highlights: SolarEdge, Intuitive Surgical, Knight-Swift, HPE, and moreNASDAQ:SGENSeagen Inc
16/10/202314:00Business WireSeagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023NASDAQ:SGENSeagen Inc
12/10/202314:00Business WireSeagen to Report Third Quarter 2023 Financial Results on November 1, 2023NASDAQ:SGENSeagen Inc
22/09/202313:02Dow Jones NewsMerck, Seagen, Astellas Phase 3 Bladder Cancer Study Hits EndpointsNASDAQ:SGENSeagen Inc
22/09/202311:00Business WirePADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) Significantly Improve Overall Survival and Progression-Free Survival in Patients With Previously Untreated Advanced Bladder Cancer in Pivotal Phase 3 EV-302 TrialNASDAQ:SGENSeagen Inc
18/09/202313:25IH Market NewsMonday’s Wall Street Highlights: Cisco Systems, GM, Alibaba, SVB Financial, Clorox and MoreNASDAQ:SGENSeagen Inc
04/09/202321:00Business WireSeagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy AloneNASDAQ:SGENSeagen Inc
04/09/202321:00Business WireGenmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapyNASDAQ:SGENSeagen Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SGEN
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network